US 11,939,395 B2
Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38
Michael Tesar, Freidberg (DE); and Ute Jäger, Munich (DE)
Assigned to Morphosys AG, Planegg (DE)
Filed by MORPHOSYS AG, Planegg (DE)
Filed on Jun. 9, 2021, as Appl. No. 17/343,163.
Application 14/877,958 is a division of application No. 13/918,199, filed on Jun. 14, 2013, granted, now 9,193,799, issued on Nov. 24, 2015.
Application 13/918,199 is a division of application No. 13/291,473, filed on Nov. 8, 2011, granted, now 8,486,394, issued on Jul. 16, 2013.
Application 13/291,473 is a division of application No. 12/089,806, granted, now 8,088,896, issued on Jan. 3, 2012, previously published as PCT/EP2006/009889, filed on Oct. 12, 2006.
Application 17/343,163 is a continuation of application No. 16/125,307, filed on Sep. 7, 2018, granted, now 11,059,902.
Application 16/125,307 is a continuation of application No. 14/877,958, filed on Oct. 8, 2015, granted, now 10,184,005, issued on Jan. 22, 2019.
Claims priority of provisional application 60/725,297, filed on Oct. 12, 2005.
Prior Publication US 2021/0292431 A1, Sep. 23, 2021
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/3061 (2013.01) [C07K 16/2896 (2013.01); C07K 16/40 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01)] 6 Claims
 
1. A method for generating variants of an anti-CD38 antibody comprising a VH of SEQ ID NO: 21 and a VL of SEQ ID NO: 51, said method comprising the steps of:
i) diversifying one or more amino acid residues within one or more CDR regions or one or more framework regions of the anti-CD38 antibody comprising the VH of SEQ ID NO: 21 and the VL of SEQ ID NO: 51;
ii) generating a recombinant antibody library comprising antibodies with the one or more diversified amino acid residues; and
iii) screening antibodies of the recombinant antibody library against a CD38 antigen.